Cannabis Users with Trauma Have 15-20% More of a Key Brain Receptor Linked to Both Conditions
PET brain imaging revealed that cannabis users with trauma-related psychopathology had 15-20% higher levels of mGlu5 receptors in frontal and limbic brain regions — a receptor at the intersection of the endocannabinoid and glutamate systems.
Quick Facts
What This Study Found
The endocannabinoid system and the glutamate system are deeply intertwined in the brain, and both are implicated in trauma-related conditions and cannabis use. This study used PET brain imaging to measure a specific receptor — metabotropic glutamate receptor 5 (mGlu5) — that sits at this intersection, in people with trauma-related psychopathology who did and didn't use cannabis.
Among 55 individuals with trauma-related mental health conditions, those who had used cannabis in the past year showed 18.6-19.1% higher mGlu5 availability in frontal brain regions and 14.2-16.6% higher levels in limbic regions (including the amygdala and hippocampus) compared to non-users. Monthly users showed similar elevations.
Why does this matter? mGlu5 receptors regulate glutamate signaling — the brain's primary excitatory system — and are directly modulated by endocannabinoids. Higher mGlu5 levels could reflect a compensatory response to cannabis exposure, an underlying vulnerability that both predisposes to cannabis use and worsens trauma responses, or an adaptive change that affects how the brain processes threatening information.
The orbitofrontal cortex and amygdala — two regions showing elevated mGlu5 — are central to threat processing, emotional regulation, and the fear circuitry disrupted in PTSD. If cannabis use alters glutamate receptor levels in these specific regions, it could change how trauma survivors process threatening stimuli and regulate emotional responses.
This is the first study to directly investigate the cannabis-mGlu5 relationship in people with trauma-related conditions, opening a new molecular window into why cannabis and trauma are so frequently linked.
Key Numbers
55 participants with trauma-related psychopathology. Past-year cannabis users (n=22): 18.62-19.12% higher mGlu5 in frontal ROIs, 14.24-16.55% higher in limbic ROIs. Past-month/monthly users (n=16): 18.05-20.62% higher in frontal, 15.53-16.83% higher in limbic ROIs. Key regions: orbitofrontal cortex and amygdala.
How They Did This
Cross-sectional PET imaging study using [18F]FPEB to measure mGlu5 receptor availability in vivo. 55 individuals with trauma-related psychopathology (cross-diagnostic sample). Compared mGlu5 levels in frontolimbic regions of interest (dorsolateral prefrontal cortex, orbitofrontal cortex, ventromedial prefrontal cortex, amygdala, hippocampus) between cannabis users and non-users. Tested both past-year use (n=22) and past-month/monthly use (n=16).
Why This Research Matters
Most research on cannabis and the brain focuses on the CB1 receptor. This study reveals that cannabis use also affects glutamate receptors — through a different neurotransmitter system — in brain regions critical for trauma processing. This cross-system effect could help explain why cannabis has such complex relationships with mental health: it's not just affecting the endocannabinoid system, it's reshaping glutamate signaling in emotion-regulation circuits.
The Bigger Picture
This adds a molecular dimension to the PTSD-cannabis cluster (RTHC-00116, 00117, 00125, 00127). Those studies documented the behavioral relationships — PTSD drives cannabis use, cannabis use affects treatment engagement, psychological inflexibility mediates the link. This study shows what's happening in the brain: mGlu5 receptor changes in the exact circuits that process threat and regulate emotion. It also connects to the neuroscience of the dopamine-endocannabinoid interaction (RTHC-00072, 00073) by revealing that cannabis effects extend beyond the endocannabinoid system into glutamate signaling.
What This Study Doesn't Tell Us
Cross-sectional — can't determine whether cannabis caused the mGlu5 elevation or whether higher baseline mGlu5 predisposes to cannabis use. Small sample (55 total, 22 cannabis users). Cross-diagnostic sample (various trauma-related conditions) rather than a specific diagnosis like PTSD. No healthy control group without trauma exposure. Cannabis use was categorized broadly (past-year/past-month) without dose, potency, or product data. PET imaging measures receptor availability, which reflects a combination of receptor density and binding affinity.
Questions This Raises
- ?Does cannabis directly cause mGlu5 upregulation, or do people with higher baseline mGlu5 preferentially use cannabis?
- ?Would these mGlu5 changes reverse with cannabis cessation?
- ?Could mGlu5 be a treatment target for co-occurring cannabis use and PTSD?
- ?Do the frontal mGlu5 changes affect decision-making and impulse control in trauma-exposed cannabis users?
Trust & Context
- Key Stat:
- Evidence Grade:
- Cross-sectional PET imaging study with a modest sample size. The imaging data is rigorous (validated radiotracer, well-defined regions of interest), but the cross-sectional design and small sample limit causal inference.
- Study Age:
- Published in 2024. mGlu5 as a biomarker for cannabis-trauma interaction is a novel research direction.
- Original Title:
- Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.
- Published In:
- The international journal of neuropsychopharmacology, 27(10) (2024) — The International Journal of Neuropsychopharmacology is a reputable journal focused on the intersection of neuroscience and pharmacology.
- Authors:
- Weiss, Emily R, Davis, Margaret T, Asch, Ruth H, D'Souza, Deepak Cyril, Cool, Ryan, Esterlis, Irina
- Database ID:
- RTHC-05807
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- why-does-weed-make-you-emotional-thc
- thc-and-studying-cannabis-learning-research
Cite This Study
https://rethinkthc.com/research/RTHC-05807APA
Weiss, Emily R; Davis, Margaret T; Asch, Ruth H; D'Souza, Deepak Cyril; Cool, Ryan; Esterlis, Irina. (2024). Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.. The international journal of neuropsychopharmacology, 27(10). https://doi.org/10.1093/ijnp/pyae044
MLA
Weiss, Emily R, et al. "Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.." The international journal of neuropsychopharmacology, 2024. https://doi.org/10.1093/ijnp/pyae044
RethinkTHC
RethinkTHC Research Database. "Metabotropic Glutamate Receptor 5 as a Potential Biomarker o..." RTHC-05807. Retrieved from https://rethinkthc.com/research/weiss-2024-metabotropic-glutamate-receptor-5
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.